aspirin has been researched along with Vascular Calcification in 14 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Vascular Calcification: Deposition of calcium into the blood vessel structures. Excessive calcification of the vessels are associated with ATHEROSCLEROTIC PLAQUES formation particularly after MYOCARDIAL INFARCTION (see MONCKEBERG MEDIAL CALCIFIC SCLEROSIS) and chronic kidney diseases which in turn increase VASCULAR STIFFNESS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Among current therapies, low-dose aspirin has been shown to reduce cardiovascular thrombosis." | 7.96 | A Pathophysiologic Primary Prevention Review of Aspirin Administration to Prevent Cardiovascular Thrombosis. ( Burchiel, S; Eaton, RP; Schade, DS, 2020) |
| "8 years with 10-75% coronary artery stenosis, as assessed by coronary computed tomography angiography, were randomly assigned to sarpogrelate 300 mg/day plus aspirin 100 mg/day (SPG + ASA group) or aspirin 100 mg/day alone (ASA group) for 6 months." | 5.24 | Effect of sarpogrelate, a selective 5-HT ( Chun, EJ; Han, SJ; Hur, JH; Jang, HC; Kang, DK; Kim, HJ; Kim, KM; Lee, DH; Lee, JE; Lim, S; Min, SH; Oh, TJ, 2017) |
| "To examine the association between CAC, bleeding, and ASCVD and explore the net estimated effect of aspirin at different CAC thresholds." | 4.02 | Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease. ( Ajufo, E; Ayers, CR; de Lemos, JA; Joshi, PH; Khera, A; Rohatgi, A; Vigen, R, 2021) |
| "Recent American College of Cardiology/American Heart Association Primary Prevention Guidelines recommended considering low-dose aspirin therapy only among adults 40 to 70 years of age who are at higher atherosclerotic cardiovascular disease (ASCVD) risk but not at high risk of bleeding." | 3.96 | Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The MESA Study (Multi-Ethnic Study of Atherosclerosis). ( Al Rifai, M; Blaha, MJ; Blumenthal, RS; Budoff, M; Cainzos-Achirica, M; Dardari, Z; Duprez, DA; Dzaye, O; Greenland, P; Hong, J; McEvoy, JW; Miedema, MD; Mortensen, MB; Nasir, K; Yeboah, J, 2020) |
| " Among current therapies, low-dose aspirin has been shown to reduce cardiovascular thrombosis." | 3.96 | A Pathophysiologic Primary Prevention Review of Aspirin Administration to Prevent Cardiovascular Thrombosis. ( Burchiel, S; Eaton, RP; Schade, DS, 2020) |
| "Aspirin has been the mainstay of both secondary and primary prevention of cardiovascular disease for half a century." | 2.72 | Aspirin in Primary Prevention: What Changed? A Critical Appraisal of Current Evidence. ( Dasa, O; Pearson, TA; Pepine, CJ, 2021) |
| "It is a marker of atherosclerotic plaque burden and the strongest independent predictor of future myocardial infarction and mortality." | 1.46 | Cardiac Society of Australia and New Zealand position statement executive summary: coronary artery calcium scoring. ( Chan, J; Chow, CK; Hamilton-Craig, CR; Jelinek, VM; Liew, GY; Younger, JF, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 9 (64.29) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, S | 1 |
| Belcaro, G | 1 |
| Cesarone, MR | 1 |
| Feragalli, B | 1 |
| Cotellese, R | 1 |
| Dugall, M | 1 |
| Scipione, C | 1 |
| Scipione, V | 1 |
| Maione, C | 1 |
| Paven, E | 1 |
| Dillinger, JG | 1 |
| Bal Dit Sollier, C | 1 |
| Vidal-Trecan, T | 1 |
| Berge, N | 1 |
| Dautry, R | 1 |
| Gautier, JF | 1 |
| Drouet, L | 1 |
| Riveline, JP | 1 |
| Henry, P | 1 |
| Lee, CH | 1 |
| Kim, U | 1 |
| Wokhlu, A | 1 |
| Wymer, D | 1 |
| Taasan, V | 1 |
| Winchester, DE | 1 |
| Cainzos-Achirica, M | 1 |
| Miedema, MD | 1 |
| McEvoy, JW | 1 |
| Al Rifai, M | 1 |
| Greenland, P | 1 |
| Dardari, Z | 1 |
| Budoff, M | 1 |
| Blumenthal, RS | 1 |
| Yeboah, J | 1 |
| Duprez, DA | 1 |
| Mortensen, MB | 1 |
| Dzaye, O | 1 |
| Hong, J | 1 |
| Nasir, K | 1 |
| Blaha, MJ | 1 |
| Ajufo, E | 1 |
| Ayers, CR | 1 |
| Vigen, R | 1 |
| Joshi, PH | 1 |
| Rohatgi, A | 1 |
| de Lemos, JA | 1 |
| Khera, A | 1 |
| Dasa, O | 1 |
| Pepine, CJ | 1 |
| Pearson, TA | 1 |
| Schade, DS | 1 |
| Burchiel, S | 1 |
| Eaton, RP | 1 |
| Kim, BS | 1 |
| Chan, N | 1 |
| Hsu, G | 1 |
| Makaryus, AN | 1 |
| Chopra, M | 1 |
| Cohen, SL | 1 |
| Makaryus, JN | 1 |
| Hamilton-Craig, CR | 1 |
| Chow, CK | 1 |
| Younger, JF | 1 |
| Jelinek, VM | 1 |
| Chan, J | 1 |
| Liew, GY | 1 |
| Fiaccadori, E | 1 |
| Maggiore, U | 1 |
| Regolisti, G | 1 |
| Ercan, S | 1 |
| Davutoglu, V | 1 |
| Ozer, O | 1 |
| Soeiro, Ade M | 1 |
| Mansur, Ade P | 1 |
| Schaan, BD | 1 |
| Caramelli, B | 1 |
| Rochitte, CE | 1 |
| Serrano, CV | 1 |
| Garzillo, CL | 1 |
| Calderaro, D | 1 |
| Gualandro, DM | 1 |
| Lima, EG | 1 |
| Marcondes-Braga, FG | 1 |
| Lima, FG | 1 |
| Oliveira, FM | 1 |
| Azevedo, FR | 1 |
| Chauhan, H | 1 |
| Salles, JE | 1 |
| Soares, J | 1 |
| Cardoso, JN | 1 |
| Pellanda, LC | 1 |
| Sacilotto, L | 1 |
| Baracioli, L | 1 |
| Bortolotto, LA | 1 |
| César, LA | 1 |
| Ochiai, ME | 1 |
| Minami, MH | 1 |
| Pinheiro, MB | 1 |
| Moretti, MA | 1 |
| Oliveira, MT | 1 |
| Rezende, PC | 1 |
| Lemos, PA | 1 |
| Admoni, SN | 1 |
| Lottenberg, SA | 1 |
| Rocha, VZ | 1 |
| Hueb, W | 1 |
| Mathias, W | 1 |
| Lee, DH | 1 |
| Chun, EJ | 1 |
| Hur, JH | 1 |
| Min, SH | 1 |
| Lee, JE | 1 |
| Oh, TJ | 1 |
| Kim, KM | 1 |
| Jang, HC | 1 |
| Han, SJ | 1 |
| Kang, DK | 1 |
| Kim, HJ | 1 |
| Lim, S | 1 |
1 review available for aspirin and Vascular Calcification
| Article | Year |
|---|---|
Aspirin in Primary Prevention: What Changed? A Critical Appraisal of Current Evidence.
Topics: Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Evidence-Based Medicine; Heart Disease Ri | 2021 |
1 trial available for aspirin and Vascular Calcification
| Article | Year |
|---|---|
Effect of sarpogrelate, a selective 5-HT
Topics: Adult; Aged; Ankle Brachial Index; Anti-Inflammatory Agents; Aspirin; Biomarkers; Computed Tomograph | 2017 |
12 other studies available for aspirin and Vascular Calcification
| Article | Year |
|---|---|
Central cardiovascular calcifications: supplementation with Pycnogenol® and Centellicum®: variations over 12 months.
Topics: Aspirin; Cardiovascular Diseases; Centella; Coronary Artery Disease; Dietary Supplements; Disease Ma | 2020 |
Determinants of aspirin resistance in patients with type 2 diabetes.
Topics: Aged; Arachidonic Acid; Aspirin; C-Reactive Protein; Coronary Artery Disease; Diabetes Mellitus, Typ | 2020 |
Coronary artery aneurysm in Kawasaki disease: from multimodality imaging.
Topics: Anticoagulants; Aspirin; Computed Tomography Angiography; Coronary Aneurysm; Coronary Angiography; C | 2020 |
Effect of Elevated Calcium Score on Normal Myocardial Perfusion Study on Clinician Management of Coronary Artery Disease Risk Factors.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Cohort Studies; Coronary Artery Di | 2020 |
Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The MESA Study (Multi-Ethnic Study of Atherosclerosis).
Topics: Aged; Aged, 80 and over; Aspirin; Clinical Decision-Making; Computed Tomography Angiography; Coronar | 2020 |
Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease.
Topics: Adult; Aspirin; Atherosclerosis; Cohort Studies; Coronary Artery Disease; Coronary Disease; Eye Hemo | 2021 |
A Pathophysiologic Primary Prevention Review of Aspirin Administration to Prevent Cardiovascular Thrombosis.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Humans; Plaque, Atherosclerotic; Pr | 2020 |
Sex Differences in Coronary Arterial Calcification in Symptomatic Patients.
Topics: Adult; Aspirin; Chest Pain; Cohort Studies; Computed Tomography Angiography; Coronary Angiography; C | 2021 |
Cardiac Society of Australia and New Zealand position statement executive summary: coronary artery calcium scoring.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asymptomatic Diseases; Coronary Artery Disea | 2017 |
Balancing thromboembolic risk against vitamin K antagonist-related bleeding and accelerated calcification: is fondaparinux the Holy Grail for end-stage renal disease patients with atrial fibrillation?
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Contraindications; Factor Xa Inhibitors; Fondaparinux; | 2013 |
Breakage of floppy wire during coronary stenting and long-term outcome.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheters; Coronary Angiography; Coronary Artery Di | 2013 |
Topics: Aspirin; Atherosclerosis; Brazil; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitu | 2014 |